Wall Street brokerages expect AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) to post sales of $2.90 million for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for AcelRx Pharmaceuticals’ earnings, with estimates ranging from $2.70 million to $3.10 million. AcelRx Pharmaceuticals reported sales of $6.44 million in the same quarter last year, which indicates a negative year over year growth rate of 55%. The company is expected to issue its next earnings report on Thursday, March 1st.

According to Zacks, analysts expect that AcelRx Pharmaceuticals will report full year sales of $2.90 million for the current year, with estimates ranging from $10.00 million to $11.27 million. For the next fiscal year, analysts forecast that the firm will report sales of $9.10 million per share, with estimates ranging from $6.90 million to $11.30 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover AcelRx Pharmaceuticals.

ACRX has been the topic of several recent analyst reports. Royal Bank Of Canada set a $6.00 price target on AcelRx Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 25th. ValuEngine lowered AcelRx Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, September 15th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of AcelRx Pharmaceuticals in a research report on Tuesday, October 3rd. Piper Jaffray Companies restated a “hold” rating and set a $2.00 price target on shares of AcelRx Pharmaceuticals in a research report on Friday, October 13th. Finally, Stifel Nicolaus upgraded AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. AcelRx Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $6.83.

In other AcelRx Pharmaceuticals news, Director Mark G. Edwards acquired 30,000 shares of the stock in a transaction dated Tuesday, November 14th. The stock was purchased at an average price of $1.90 per share, with a total value of $57,000.00. Following the transaction, the director now directly owns 150,000 shares of the company’s stock, valued at $285,000. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Lawrence G. Hamel sold 10,161 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $5.29, for a total value of $53,751.69. Following the completion of the transaction, the insider now owns 16,379 shares of the company’s stock, valued at approximately $86,644.91. The disclosure for this sale can be found here. In the last three months, insiders purchased 42,000 shares of company stock worth $89,380. 28.10% of the stock is owned by insiders.

Several large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its holdings in AcelRx Pharmaceuticals by 6.6% in the 1st quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock worth $355,000 after buying an additional 6,942 shares during the last quarter. Perennial Advisors LLC purchased a new stake in AcelRx Pharmaceuticals in the third quarter valued at approximately $138,000. WealthTrust Axiom LLC increased its position in shares of AcelRx Pharmaceuticals by 50.0% during the second quarter. WealthTrust Axiom LLC now owns 210,000 shares of the specialty pharmaceutical company’s stock worth $451,000 after acquiring an additional 70,000 shares during the period. Geller Family Office Services LLC purchased a new stake in shares of AcelRx Pharmaceuticals during the third quarter worth $460,000. Finally, Virtu KCG Holdings LLC increased its position in shares of AcelRx Pharmaceuticals by 600.9% during the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock worth $255,000 after acquiring an additional 101,742 shares during the period. Hedge funds and other institutional investors own 13.94% of the company’s stock.

Shares of AcelRx Pharmaceuticals (ACRX) traded down $0.05 on Tuesday, reaching $2.20. The company had a trading volume of 1,019,600 shares, compared to its average volume of 987,612. The company has a debt-to-equity ratio of -0.43, a quick ratio of 4.71 and a current ratio of 4.78. AcelRx Pharmaceuticals has a twelve month low of $1.55 and a twelve month high of $5.75.

TRADEMARK VIOLATION WARNING: This piece was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/12/05/2-90-million-in-sales-expected-for-acelrx-pharmaceuticals-inc-acrx-this-quarter.html.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.